Victory Capital Management Inc. boosted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 10.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,272 shares of the company's stock after acquiring an additional 4,009 shares during the period. Victory Capital Management Inc. owned 0.05% of DaVita worth $6,471,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. MML Investors Services LLC lifted its position in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after acquiring an additional 68 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after acquiring an additional 68 shares during the last quarter. Impact Partnership Wealth LLC lifted its position in DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after acquiring an additional 70 shares during the last quarter. Contravisory Investment Management Inc. lifted its position in DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after acquiring an additional 73 shares during the last quarter. Finally, Nilsine Partners LLC lifted its position in DaVita by 0.8% during the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after acquiring an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.
Analyst Ratings Changes
A number of research analysts have issued reports on DVA shares. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $166.33.
Read Our Latest Research Report on DVA
DaVita Stock Performance
Shares of NYSE:DVA traded up $0.03 during midday trading on Tuesday, reaching $149.27. The company's stock had a trading volume of 673,871 shares, compared to its average volume of 780,848. The firm has a market capitalization of $11.94 billion, a PE ratio of 13.90, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The stock has a fifty day moving average of $158.87 and a 200 day moving average of $157.62. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
